ARTVArtiva Biotherapeutics, Inc.

ARTV Stock Price, Valuation & Chart | Artiva Biotherapeutics, Inc.

Compare

$11.310+0.03 (+0.27%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ARTV intrinsic value ARTV calculated fair value vs price

Overview Financials Dividends Ratios

ARTV Historical price chart

ARTV Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization552.95M

PE Ratio-3.43

EPS-3.3

Trading Volume306.52K

Today's High/Low11.51/11.05

Dividend Yield0.00

52 Week High/Low14.53/2.22

Shares Outstanding48.89M

ARTV Financial Statement

ARTV Analyst ratings

ARTV Analysis & performance metrics

ARTV Company profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune…

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus…

ARTV Management team

Name

Position

Peter Flynn Ph.D.

Co-Founder & Strategic Advisor

Heather Raymon Ph.D.

Senior Vice President of Research & Early Development

Benjamin Dewees

Senior Vice President of Regulatory Affairs

Feng Xu

Senior Vice President of Biometrics

Fred Aslan M.D.CEO

President, Chief Executive Officer & Director

Neha KrishnamohanCFO

Chief Financial Officer & Executive Vice President of Corporate Development

Jennifer Kinsbruner Bush Esq., J.D.COO

Executive Vice President, Chief Operating Officer, Chief Legal Officer, Corporate Secretary & Compliance Officer

Christopher P. Horan

Chief Technical Operations Officer

Name

Position

Peter Flynn Ph.D.

Co-Founder & Strategic Advisor

Heather Raymon Ph.D.

Senior Vice President of Research & Early Development

Benjamin Dewees

Senior Vice President of Regulatory Affairs

Feng Xu

Senior Vice President of Biometrics

Fred Aslan M.D.CEO

President, Chief Executive Officer & Director

Neha KrishnamohanCFO

Chief Financial Officer & Executive Vice President of Corporate Development

Jennifer Kinsbruner Bush Esq., J.D.COO

Executive Vice President, Chief Operating Officer, Chief Legal Officer, Corporate Secretary & Compliance Officer

Christopher P. Horan

Chief Technical Operations Officer

Management Team

Peter Flynn Ph.D.

Co-Founder & Strategic Advisor

Heather Raymon Ph.D.

Senior Vice President of Research & Early Development

Benjamin Dewees

Senior Vice President of Regulatory Affairs

Feng Xu

Senior Vice President of Biometrics

Fred Aslan M.D.CEO

President, Chief Executive Officer & Director

Neha KrishnamohanCFO

Chief Financial Officer & Executive Vice President of Corporate Development

Jennifer Kinsbruner Bush Esq., J.D.COO

Executive Vice President, Chief Operating Officer, Chief Legal Officer, Corporate Secretary & Compliance Officer

Christopher P. Horan

Chief Technical Operations Officer

Management

Peter Flynn Ph.D.

Co-Founder & Strategic Advisor

Heather Raymon Ph.D.

Senior Vice President of Research & Early Development

Benjamin Dewees

Senior Vice President of Regulatory Affairs

Feng Xu

Senior Vice President of Biometrics

Fred Aslan M.D.CEO

President, Chief Executive Officer & Director

Neha KrishnamohanCFO

Chief Financial Officer & Executive Vice President of Corporate Development

Jennifer Kinsbruner Bush Esq., J.D.COO

Executive Vice President, Chief Operating Officer, Chief Legal Officer, Corporate Secretary & Compliance Officer

Christopher P. Horan

Chief Technical Operations Officer

Total 8 executives

ARTV Frequently asked questions

What is Artiva Biotherapeutics, Inc. (ARTV) Stock Price?

Current stock price of Artiva Biotherapeutics, Inc. (ARTV) stock is $11.310. The stock price is +0.27% higher in the session. The intraday range can be seen from this page. Volume of Artiva Biotherapeutics, Inc. (ARTV) stock is 306.52K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Artiva Biotherapeutics, Inc. (ARTV) stock price going up or down today?

The stock price of Artiva Biotherapeutics, Inc. (ARTV) can change with earnings, company news, and overall market sentiment. Artiva Biotherapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Artiva Biotherapeutics, Inc. stock expensive at its current price?

Whether Artiva Biotherapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ARTV on this page is -3.43. EPS on this page is -3.30. Compare those figures with peers and growth expectations before deciding if the current Artiva Biotherapeutics, Inc. price is justified.

How has the stock price of Artiva Biotherapeutics, Inc. (ARTV) performed historically?

Historical performance for Artiva Biotherapeutics, Inc. (ARTV) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ARTV reacted to past earnings and market events.

Should I buy Artiva Biotherapeutics, Inc. (ARTV) stock, at this price?

Buying Artiva Biotherapeutics, Inc. (ARTV) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.